Sanofi is currently trading at a low price-to-earnings ratio of 8.4 despite having a strong AA credit rating, a solid balance sheet, and a 5.8% dividend yield. The perceived risks to its drug pipeline are considered overstated, with growth driven by the expansion of Dupixent and several smaller product launches expected through 2028. Even without blockbuster new drugs, Sanofi is projected to offer over 15% annualized upside based on normalized earnings and historical valuation multiples. The analyst maintains a Buy rating with a price target of €95 per share and a fair value estimate of €120 per share, highlighting a compelling risk/reward profile at current prices.
Sanofi shares are trading at USD 41.34 with a 4.47% gain on Pluang as of Oct 21, 2026 02:41 WIB, showing strong investor interest. The stock offers a 6.12% dividend yield, higher than the 5.8% mentioned in the article, and has a market cap of $95.49 billion. This robust trading activity aligns with the article's view that pipeline risks may be overestimated, supporting a positive outlook for the stock.
Japan's Ministry of Health has approved Sanofi's CirCLIQ Injector, developed with Enable Injections' enFuse On-Body Delivery System, for administering Sarclisa subcutaneous formulation to treat multiple myeloma. This marks Enable's first commercial p...
Sanofi has begun construction of a cutting-edge insulin manufacturing facility at its BioCampus in Frankfurt, Germany, aiming for full production by 2032. This new plant will enhance Sanofi's ability to supply insulin reliably to millions worldwide, ...
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
